A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

This study is testing a chemoradiation treatment (combining radiation with two chemotherapy drugs — mitomycin-C and capecitabine) for people with muscle-invasive bladder cancer who want to keep their bladder, comparing this regimen to standard approaches to see if it is safer and more effective. **You may be eligible if...** - You are 18 or older and have been diagnosed with muscle-invasive bladder cancer (cancer that has grown into the muscle layer of the bladder), stage T2–T4a, with no distant spread - You want to preserve your bladder (rather than have it removed), OR you are not a candidate for bladder removal surgery - You have had as much of the bladder tumor removed as safely possible through a scope procedure (TURBT) within the past 35 days - You are in good health (ECOG performance status 0 or 1) - Your kidneys, liver, and blood counts are functioning adequately **You may NOT be eligible if...** - Your tumor is not primarily urothelial (bladder lining) cell type - You have not had a surgical attempt to remove the tumor before starting treatment - You have active infections or conditions that prevent treatment - You are unable to have regular follow-up cystoscopies (bladder camera checks) Talk to your doctor to see if this trial is right for you.